Avel S.’s Post

Pharmaceutical Launch Leaders, are you making enough noise in your target market? At Trilations, we delve into the influence of familiarity on launch success in different regions and therapeutic areas to help your team navigate this critical driver of success. Understanding the role of product familiarity can be crucial for a successful global drug launch. This crucial first step of achieving a high product familiarity is key for a strong adoption in the market. During our recent Launch webinar Douglas Black underlined the importance of 'getting it right' from the beginning: "A drug approval is like a unicorn. It's very precious, not only to the company but most importantly to the patient, and you have to get it right." Learn from Michiel Dockx, Launch Excellence Lead at Trilations, his key findings and strategies are invaluable to leverage HCPs' familiarity with new brands for a more impactful launch. Discover the steps you can take to ensure your product resonates with the target market and achieves its full potential on a global and regional scale. Get in contact with Michiel: https://loom.ly/9lNWHLY In this whitepaper our Launch Excellence Lead, Michiel, dives into key findings and strategies that are invaluable to leverage awareness for a more impactful launch. Discover the insights here: https://loom.ly/1dcv2EE This is part 1 of Trilations' Pharma Launch Excellence series. Save this post and make sure to see the following insights. #Pharma #Trilationslaunch #hcpeducation #patientcare #productawareness #launchexcellence

Insights on the importance of effective HCP education in launching successful pharma products with a strong uptake and maximal peak sales. It’s vital to ensure that healthcare professionals are equipped with the right knowledge to better serve patients. A good launch strategy can make all the difference!

💡💡💡 Getting a strong uptake after market entry is crucial for any pharma drug to become successful in a competitive environement. An essential prerequisite to achieve this is to inform and educate your target customers about your product well upfront, making them set realistic standards for when they would starting to prescribe your product. At Trilations Healthcare Strategies, we draw insights from a global database of HCPs' perceptions of over 300 launches in the past 5 years. Interested to learn more? Feel free to contact me via a personal message. #pharma #drugs #launch

💡 Value of Anticipation: Drug development for go-to-market 🚀 In a lot of my conversations in pharma, one word keeps popping up: anticipation. Every launch I've supported sparks the same conversation: What could we have done differently in development? 💬 I often hear launch teams saying things like, 'Our data isn't cutting it for the price we want,' 'Doctors struggle to identify patients to switch to our drug.', 'We cannot counter competitor claims', or 'We have to go through lenghty variation management to fit with pharmacopeia requirements'. 🤷♀️ These hurdles remind us that clinical development is focused on 1 single KPI : getting approval, along with pressure on time & cost. But this sometimes means we miss the bigger picture So, here's the deal: We need to start anticipating: 1️⃣ **Pharmacopeia Requirements:** Bring in pharmacopeia experts at time of TPP finalization to spot and tackle roadblocks early. 2️⃣ **Market Access Needs:** Plan our data generation thinking about market access, keeping up with changing rules and what payers are looking for. The EU HTA reform will be a good test for that! 3️⃣ **Differentiation & market activation:** Make sure our development stands out by keeping it close to how our drug fits into the real world and how we stack up against rivals. 🚗 Take inspiration from the car industry: get it right from the get-go. What's the recurring headache in your line of work, and how do you handle it? Olivier Vitoux Thierry de Fougerolles Flora Leadley Stéphanie De Man Erik Saey

Prasanna Kumar Subbanna will be joining us at #TheMachinecon2024. He is a seasoned physician and business executive with over two decades of distinguished experience in the healthcare and pharmaceutical R&D sectors. With a profound understanding of the global value chain, his expertise spans clinical development, product launches, and bedside care, underscoring a comprehensive approach to healthcare innovation and patient outcomes. He will share his insights on "The Role of #GCCs in Healthcare Innovation" in an interesting panel Discussion. Novo Nordisk

Don’t miss tomorrow’s webinar with the HealthXL community discussing the potential of digital measures to revolutionize drug development. Pharma has been slow to fully utilize these measures due to their high costs and lack of standardized applications across therapeutic areas. Experts also believe that a lack of patient and HCP awareness as well as a shortage of technical expertise is currently holding the industry back. Secure your spot now to learn more about how we can come together to ensure better utilization of digital measures in clinical trials. ➡️ https://lnkd.in/e9Hrgn-9 I #DigitalMeasures #DigitalClinicalTrials #DigitalHealth #DrugDevelopment #FutureOfMedicine Maulik Majmudar, M.D.

💡 Since 2016, over 100 #clinical trial supply chain stakeholders have worked to develop industry #standards. To ensure efficient clinical trials, stakeholders must adopt standards-based #identification for products, locations, and parties. The Global Location Number (#GLN) streamlines accurate delivery of investigational products. With proven #success in the commercial healthcare sector, it's time for the clinical trials supply chain to adopt global location identification standards. #Read this important statement from the GS1 Healthcare Clinical Trials Implementation Group, supported by Boehringer Ingelheim, Creapharm, a Myonex company, DHL, Johnson & Johnson, Pfizer, Roche and Sanofi. 🔗 Read the document here 👉 https://bit.ly/3Vz3w6e 🔗 Learn more here 👉 https://bit.ly/3Jfh4P1 #AdoptGLNsNow #GS1InClinicalTrials #GS1Healthcare #ClinicalTrials

The adoption of the Global Location Number (GLN) within the clinical trial supply chain marks a significant leap forward in ensuring the accuracy and efficiency of product deliveries. As Le Rudulier N., Head of Innovation and Group Synergy Development & IT at Creapharm stated, “It is for this reason that today we have dedicated to this standardisation and use the GS1 DataMatrix dedicated to the clinical trial products.” Collaboration among industry leaders has been crucial in driving this change as we are setting a new benchmark for how clinical trial supplies are managed globally. View the article below to learn more about the GLN initiative. #ClinicalTrials #GS1 #AdoptGLNsNow

The Shift to Value-Based Drug Pricing in the United States 🌐 The U.S. is leading a significant shift in healthcare: value-based drug pricing. 🏥💡 This change is crucial for aligning medication costs with their true value to society and ensuring sustainable healthcare innovation. 🔍 Discover how this approach can shape the global market and support the development of essential medicines. 🔗 Learn more about the implications and strategies for a value-centric future in our latest article. #ValueBasedHealthcare #DrugPricing #HealthcareInnovation #PharmaMarketAccess #LifeSciencesConsulting 📈 Join the dialogue and let's shape a healthcare system that truly values health outcomes and innovation. Read the full article here and share your insights! 💬 https://lnkd.in/d8dqyywv

What does the EU Pharma Package mean for your company? Will it "incentivize innovation and improve access to medicines," or will the reductions in marketing exclusivity, requirements to launch in all 27 EU markets within 2 years, and the revision of orphan status and incentives as well as the proposed definition of High Unmet Medical Need lead to a drop in valuations, make some business models un-investible, and reduce access to medicines for patients? This legislation will come into force one way or another, and will have a massive impact, including on your company. Is there scope to improve the legislation or is it already too late, and what does it mean for your company? Broadreach Global is proud to organize this important discussion session . Join us at BiotechGate Digital Partnering on February 27 - register for free for the partnering and the program sessions at https://lnkd.in/g6iUcxUS Katja Murray FTI Consulting Sally Shorthose Bird & Bird Mark Treherne Monument Therapeutics Antoine Mialhe Graham Combe Patrik Frei Conor Duffy